Peter Heerma

Peter Heerma

Chief Commercial OfficeratTravere Therapeutics· In proxies 2021–2025

Pay in FY2025Travere Therapeutics stock +119.3% the same year

Peter Heerma was paid $2.3M in FY2025 (Dec). Travere Therapeutics stock rose 119.3% that year.

Pay$100 in the stock at the end of FY20 → $169
Pay is from the Summary Compensation Table of each Travere Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Travere TherapeuticsPublic company · 5 yr
    • Chief Commercial Officer2021 – Present · 5 yrStock in role +84%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

Two people shown as one, or a wrong number?